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Penzel et al.1 recently described a lung adenocarcinoma patient with 
an EML4-ALK fusion between exon 
6 of echinoderm microtubule associ-
ated protein like 4 (EML4) and exon 19 
of anaplastic lymphoma kinase (ALK) 
(E6;A19) as a novel molecular variant. 
It should be noted that this EML4-ALK 
(E6;A19) fusion has been previously 
reported by our group in a 62-year-old 
woman also with lung adenocarcinoma.2 
The second finding of this atypical 
EML4-ALK breakpoint (the majority of 
ALK gene fusions occur at exon 20 of 
ALK) suggests that it may not be an iso-
lated event, and highlights the great diver-
sity of fusion events involving this gene. 
Furthermore, an FN1-ALK gene fusion 
was previously identified in a malignant 
stromal sarcoma patient, in which the 
fusion also occurs at exon 19 of ALK.3 
The significance of these ALK exon 19 
fusion variants is currently unknown, 
but is interesting as it expresses the ALK 
transmembrane domain. The subcellular 
localization of these exon 19-containing 
variants should be further investigated to 
better understand the implications of this 
finding; prior evidence suggests EML4-
ALK (E13;A20) is localized within the 
cytoplasm.4 Oncogenic fusions involv-
ing ROS1 and RET in lung cancer have 
been shown previously to also include 
the transmembrane domain in some 
instances.5 The patient described by our 
group demonstrated a partial response 
to crizotinib and experienced a pro-
gression free survival of approximately 
6.5-months, supporting the argument 
that these patients be considered for ALK 
inhibitor therapy like other patients who 
are positive for ALK rearrangements.2
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In Response:
We thank Le et al.1 for their comment 
on our recent article on a rare variant of 
an EML4-ALK fusion between exon 6 of 
EML4 and exon 19 of ALK. Indeed, the 
same mutation was reported by Doebele 
et al.2 shortly before our article was 
published; this was not evident to us at 
the time we prepared and submitted our 
article. The increasing detection of rare 
EML4-ALK fusions corroborates the 
great diversity of ALK translocations 
in lung cancer and raises the need to 
further investigate the tumorbiological 
significance of these rare events and the 
patients’ responses to ALK inhibitors. 
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The reported partial response to 
Crizotinib2 provides first evidence that 
patients with exon 19-containing vari-
ants of EML4-ALK might also benefit 
from ALK inhibitors.
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To the Editor:
The optimal treatment of patients 
with locally advanced lung cancer 
remains to be defined. Combined modal-
ity treatment, usually with concomitant 
chemotherapy and radiation therapy, 
is administered usually as definitive 
therapy for patients who are poor sur-
gical candidates. Currently, available 
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data indicate that combined modality 
therapy, when feasible, is superior to 
either single modality alone; 
concomitantly administered 
chemotherapy and radiation therapy are 
superior to sequential therapy, although 
at the risk of increased toxicities.1,1 We 
initiated this phase I trial of weekly 
intravenous topotecan in increasing 
dosing cohorts with a standard 
fractionation regimen of external beam 
thoracic radiation in patients with stage 
IIIA/B lung cancer to determine the 
profile of adverse effects and a potential 
phase II dose. Prior treatment (except 
chest radiotherapy) for metastatic 
disease was allowed, provided treatment 
had reduced the burden of such disease 
to that which could be encompassed 
within a tolerable radiation port. Other 
eligibility criteria included an Eastern 
Cooperative Oncology Group 
Performance Status &les; 2; aged 18 
years or older; and adequate end-organ 
function. All patients were required to 
provide a signed informed consent form 
approved by the University of New 
Mexico Institutional Review Board. 
Patients were entered in successive 
cohorts of 3&ndash;6 into escalating 
dose levels. Topotecan was administered 
intravenously over 30 minutes, once a 
week during the radiation. The starting 
dose for the first cohort was 2 
mg/m2/wk. The planned increment 
between cohorts was 1 mg/m2/wk if no 
toxicity related to topotecan occurred, 
and 0.5 mg/m2 if grades 1&ndash;2 
toxicity occurred. All patients received a 
total radiation dose of 63 Gray as 1.8 
Gray in 35 daily fractions with a 3D 
conformal technique. Elective 
irradiation of any 18-
fluorodeoxyglucose-nonavid lymph 
node was not allowed unless the short 
axis of the node of interest was &gt;1.5 
cm on the computed tomography scan. 
Radiotherapy interruptions were only 
permitted for grade 4 
esophagitis/mucositis or skin toxicity 
and/or &ge;grade 3 pulmonary toxicity. 
The protocol was terminated 
prematurely as two out of the first six 
patients (both in the second dose cohort) 
in this study experience severe 
pneumonitis, and one of the cases was 
fatal. This precluded further evaluation 
of this dose (3 mg/m2/wk) and schedule 
or any additional planned dose 
escalation. Five of the patients were able 
to complete therapy as planned. Three of 
the patients experienced a complete 
remission by positron emission 
tomography criteria with resolution of 
all FDG-avid disease, and two of them 
experienced complete remission by 
computed tomography criteria. One 
patient is still alive and free of disease at 
last evaluation at 32 months. The 
remainder succumbed to their disease at 
a median of 11 months (range, 
3&ndash;32 months). A phase II 
topotecan dose of 2 mg/m2/wk with 
external beam thoracic radiation therapy 
could be further evaluated, but is likely 
to be below an optimal antineoplastic 
dose, at least as a single agent. Other 
regimens utilizing alternate topotecan 
doses and schedules have been shown to 
be better tolerated and should form the 
basis of regimens for further 
investigation with radiation 
therapy.3&ndash;5 
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